What Gebro Pharma does

Gebro Pharma is a privately held, family-owned pharmaceutical group headquartered in Fieberbrunn, Tyrol, Austria, operating through the strategic holding entity Gebro Holding GmbH. Founded in 1947/1948 and now in its third generation of family ownership, the group markets a portfolio of prescription (Rx) and over-the-counter (OTC) pharmaceutical products across multiple therapeutic areas, with particular specialization in dexibuprofen-based analgesics (Seractil, Seractiv, Tradil, Atriscal, Deltaran), desmopressin antidiuretic products (Nocutil), alprostadil cardiovascular formulations (Pridax, Alprostapint, Alprestil, Alplistint), antihistamines (Tavegil, Histakut), local anesthetics (Xyloneural, Dolanaest), and related specialty pharmaceuticals. Distribution is conducted through a dual model: direct sales via wholly-owned subsidiaries in Austria, Spain, and Switzerland, and licensing-out arrangements with local pharmaceutical distributors in over 30 additional countries spanning Western, Central, and Southern Europe, LATAM, and parts of Asia.

The group's revenue model combines direct pharmaceutical product sales through its three core subsidiaries with licensing royalties and supply arrangements from international partners, channeled via pharmaceutical distributors, the Haleon - Gebro Austria consumer health partnership, and the acquired Alpinamed Switzerland brand. Its product strategy emphasizes patent and brand portfolio protection, multiple dosage forms (film-coated tablets, sprays, injections, syrups, drops, powders for oral suspension), and lifecycle extension across jurisdictions. Pricing is not publicly disclosed and varies by market and regulatory regime; commercial motion is almost entirely B2B through distribution intermediaries rather than direct-to-consumer.

Ownership and capital structure are notable: Gebro Holding GmbH coordinates the subsidiaries, guards owner-defined values, and is structured to keep operating assets and intellectual property independent of country-specific operational risks. The company has deliberately remained independent for over 75 years without external investment, supporting its stated innovation strategy and long-term European employment commitments. No public revenue, headcount trend, or funding data are disclosed, and no AI/ML capabilities, digital products, or technology integrations are documented in the source material.

Name

Gebro Pharma

Legal name

Gebro Holding GmbH

Website

https://gebro.com

Company type

Private

Founded year

1948

Operating status

Operating

Headcount range

251–500 employees

Short description

Gebro Pharma is a family-owned Austrian pharmaceutical group (Gebro Holding GmbH) that markets branded Rx and OTC medicines across pain, antidiuretic, cardiovascular, and specialty therapeutic areas, distributing directly via subsidiaries in Austria, Spain, and Switzerland and through licensing partners in 30+ additional countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Branded pharmaceuticals
• Prescription medications
• OTC products
• Drug licensing
• Pharmaceutical manufacturing

Headquarters

HQ city

Fieberbrunn

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Direct sales of branded pharmaceutical products through subsidiaries in Austria, Spain, and Switzerland. Products include prescription medications (Rx) and over-the-counter (OTC) formulations across therapeutic areas including analgesics, antidiuretics, and cardiovascular treatments.
2. Licensing-out: Licensing of proprietary pharmaceutical products to distributors and partners in international markets. Products licensed include dexibuprofen formulations (Seractil, Tradil, Atriscal), desmopressin acetate (Nocutil, Desmopressin), and alprostadil formulations (Pridax, Alprestil) across over 30 countries.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Gebro Pharma manufactures and distributes branded pharmaceutical products, including both prescription (Rx) and over-the-counter (OTC) medications spanning multiple therapeutic areas such as analgesics (dexibuprofen-based), antidiuretics (desmopressin), cardiovascular agents (alprostadil), antihistamines, and anesthetics. The company supplies these products through owned subsidiaries in Austria, Spain, and Switzerland, and through international licensing partnerships across more than 30 countries.

Product overview

Gebro Pharma is a family-owned international pharmaceutical company operating under Gebro Holding GmbH. The company's product portfolio comprises prescription medications (Rx) and over-the-counter (OTC) pharmaceutical products across multiple therapeutic areas including analgesics/NSAIDs (Seractil®, Seractiv®, Tradil®, Atriscal®, Deltaran®), cardiovascular/vascular agents (Alprostapint®, Alprestil®, Alplistint®, Pridax®), antihistamines (Histakut®, Tavegil®), anesthetics (Xyloneural®, Dolanaest®), endocrine therapies (Nocutil®, Desmopressin®), respiratory treatments (Theospirex®, Makatussin® products), and specialty pharmaceuticals (Metoject®, Duplaxil®, Diliban®). The company operates through regional subsidiaries in Austria, Spain, and Switzerland, with products distributed in over 30 countries worldwide. The portfolio includes both branded innovative products and generic pharmaceutical formulations.

Differentiator

Problem solved

Functional benefit

Products and services

• Seractil Branded analgesic containing dexibuprofen for pain management, marketed across multiple European markets as a prescription NSAID.
• Nocutil Antidiuretic product based on desmopressin for the treatment of nocturia and related urinary disorders.
• Alprostapint / Alprestil / Alplistint Branded formulations of alprostadil used in cardiovascular and peripheral vascular indications.
• Metoject Methotrexate-based product indicated for rheumatic and autoimmune conditions, distributed across European markets.
• Tavegil Antihistamine product (clemastine) for allergic conditions, sold as both Rx and OTC formats.
• Xyloneural / Dolanaest / Eu-Med Local anesthetic products used for pain management in clinical and dental procedures.
• Normolyt / Normolytoral / Rehydratiezout Oral rehydration solutions for the treatment of fluid and electrolyte loss due to diarrhea and dehydration.
• Sanalgin N / Makatussin / Makatussin Comp Established consumer health brands covering analgesics and cough/cold symptom relief, marketed primarily in Austrian and regional European markets.
• Theospirex / Diliban / Duplaxil Respiratory and bronchial therapy products used for the treatment of asthma, COPD, and related conditions.
• Halset / Histakut / Deltaran Consumer health and dermatological products for throat, skin, and allergic indications.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Haleon - Gebro AustriacoreChannel Partner/ Reseller/ DistributorHaleon partnership represents a significant channel relationship for Gebro Pharma Austria, distributing pharmaceutical products through this major consumer healthcare company.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Almirall: Spanish specialty pharmaceutical company focused on branded dermatology and specialty care products sold across Europe. Highly comparable as a mid-sized, Europe-anchored specialty pharma with a branded portfolio distributed via subsidiaries and partners.
• Stada Arzneimittel: German-based generics and specialty pharma group with branded and generic products sold across Europe and international markets. Comparable as a privately held (PE-backed) mid-cap European pharma with a diversified portfolio and licensing/distributor model.
• Zambon: Italian privately-held pharmaceutical company with branded products across CNS, respiratory, and specialty therapeutic areas, distributed globally. Comparable as a family-influenced mid-sized European branded pharma with international licensing arrangements.
• KRKA: Slovenian generic and specialty pharmaceutical manufacturer with a broad branded-generic portfolio sold across Central/Eastern Europe and international markets. Comparable as a Central European mid-cap pharma combining branded generics with licensing-driven international expansion.
• Kern Pharma: Spanish generic and specialty pharmaceutical company offering a broad branded-generic portfolio across multiple therapeutic areas. Comparable as a Spain-based mid-sized pharma with branded generics distributed via partners across Europe and LATAM.
• Rottapharm: Italian privately-held pharmaceutical company with branded products in musculoskeletal, pain, and specialty areas. Comparable as a privately-owned mid-sized European specialty pharma with branded Rx portfolio and international distribution via subsidiaries and partners.
• Italfarmaco: Italian privately-held pharmaceutical company developing and marketing branded specialty products across multiple therapeutic areas including rare diseases. Comparable as a family-influenced mid-sized European specialty pharma with international partner distribution.
• Recordati: Italian-headquartered specialty and rare disease pharmaceutical group with a broad branded portfolio across multiple therapeutic areas, distributed internationally. Closely comparable business model of mid-sized European specialty pharma with geographic licensing and own-market presence.

Broad incumbents

• Gedeon Richter: Hungarian-headquartered specialty and generics pharmaceutical group with branded Rx products across CNS, women's health, and cardiovascular areas, distributed globally. Comparable European pharma with branded specialty portfolio and significant licensing/distributor footprint.
• Vifor Pharma (CSL Vifor): Swiss specialty pharmaceutical company focused on iron deficiency, nephrology, and rare disease therapies. Comparable as a Swiss-headquartered specialty pharma with branded Rx products and international licensing; broader and larger in scale than Gebro.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/gebro-pharma-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gebro Pharma